Core Viewpoint - The article highlights the successful results of two Phase III clinical studies conducted in China, demonstrating the efficacy and safety of a new diabetes medication, Masitide, developed jointly by Chinese and American pharmaceutical companies [1] Group 1: Clinical Research Findings - The studies confirmed that Masitide outperformed both placebo and Dulaglutide in controlling blood sugar levels and promoting weight loss [1] - Masitide also showed improvements in various cardiovascular metabolic, liver, and kidney-related indicators [1] Group 2: Drug Development Collaboration - Masitide is a dual receptor agonist for glucagon (GCG) and glucagon-like peptide-1 (GLP-1), co-developed by Innovent Biologics from China and Eli Lilly from the United States [1]

Core Viewpoint - The articles published in the British journal "Nature" highlight the efficacy and safety of a new diabetes medication, developed collaboratively by Chinese and American pharmaceutical companies, in treating type 2 diabetes patients [1] Group 1: Clinical Research Findings - Two phase III clinical studies involving Chinese patients with type 2 diabetes demonstrated that the drug, Masitide, outperformed both placebo and Dulaglutide in terms of blood sugar control and weight loss [1] - The studies also indicated improvements in various cardiovascular, metabolic, liver, and kidney-related indicators [1] Group 2: Drug Development and Collaboration - Masitide is a dual receptor agonist for glucagon (GCG) and glucagon-like peptide-1 (GLP-1), developed by China's Innovent Biologics in collaboration with Eli Lilly from the United States [1] - The Chief R&D Officer of Innovent Biologics, Qian Lei, stated that the research results provide high-quality evidence for overweight, obesity, and diabetes patients, showcasing China's research capabilities in this field [1] Group 3: Diabetes and Obesity Connection - Diabetes is closely related to obesity, with being overweight exacerbating insulin resistance, which is a major factor in the onset, progression, and complications of type 2 diabetes [1] - Related complications can affect blood vessels, eyes, kidneys, and feet [1]